Hospital
Integris Baptist Medical Center INC
Integris Baptist Medical Center INC was paid $30.65M by Medicaid between Jan 2018 and Nov 2024, across 121 billing codes. Its largest line is 99283, emergency room visit (moderate) — 35% of everything it billed.
33Billing provider infoINTEGRIS BAPTIST MEDICAL CENTER INC
OKLAHOMA CITY, OK 73112
OKLAHOMA CITY, OK 73112
33aNPI1831103654assigned 07/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$30.65M
24GClaims332,090
24DCodes billed121
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Oklahoma
Rank by total paid#5 of 75
Median peer was paid$3.66M
This provider vs. median8.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WEED, MICHAEL controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,364 | $2.54M | |
| 2019 | 40,418 | $4.22M | |
| 2020 | 26,616 | $2.50M | |
| 2021 | 50,868 | $4.91M | |
| 2022 | 77,943 | $7.02M | |
| 2023 | 79,347 | $6.81M | |
| 2024incomplete | 28,534 | $2.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 35% | 65,958 | 65,370 | $10.82M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 22,863 | 22,692 | $5.33M |
| D9999 | Unspecified adjunctive procedure, by report | 16% | 5,515 | 5,513 | $4.99M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 10,654 | 10,594 | $3.53M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.2% | 12,417 | 12,282 | $1.59M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.8% | 8,676 | 8,631 | $863K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 838 | 837 | $385K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 4,313 | 4,292 | $330K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,228 | 1,061 | $304K |
| 36415 | Collection of venous blood by venipuncture | <1% | 41,672 | 40,389 | $277K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,934 | 34,669 | $246K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,185 | 3,993 | $180K |
109 more codes
| 80053 | Comprehensive metabolic panel | <1% | 18,705 | $167K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,829 | $152K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,080 | $147K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,838 | $139K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 27 | $90K |
| 95819 | <1% | 278 | $78K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 565 | $76K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 735 | $72K |
| 87400 | <1% | 2,852 | $69K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,131 | $60K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 360 | $48K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,136 | $44K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 241 | $43K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 67 | $38K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,194 | $37K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,106 | $37K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,682 | $36K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 737 | $36K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 787 | $36K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 82 | $33K |
| 81001 | <1% | 10,053 | $31K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 831 | $31K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 404 | $23K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 85 | $20K |
| 87522 | Neg quan hep c or qual rna | <1% | 464 | $18K |
| 83690 | <1% | 3,111 | $18K | |
| 87430 | <1% | 1,228 | $18K | |
| 84484 | <1% | 1,430 | $16K | |
| 87070 | <1% | 1,122 | $16K | |
| 81025 | <1% | 1,872 | $13K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 486 | $13K |
| 97597 | <1% | 518 | $10K | |
| 93975 | <1% | 99 | $9K | |
| 85027 | <1% | 1,617 | $8K | |
| 82657 | <1% | 477 | $8K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 240 | $7K |
| 81003 | <1% | 3,498 | $7K | |
| 84703 | <1% | 1,091 | $7K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 142 | $6K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 60 | $6K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 82 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 122 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 447 | $5K |
| 88312 | <1% | 87 | $5K | |
| A4222 | Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) | <1% | 319 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 344 | $5K |
| 83735 | <1% | 672 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 522 | $3K |
| 83880 | <1% | 104 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 531 | $3K |
| 95811 | <1% | 12 | $3K | |
| 87420 | <1% | 228 | $3K | |
| 80143 | <1% | 173 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 85 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 85 | $3K |
| 31622 | <1% | 13 | $3K | |
| 80179 | <1% | 161 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,989 | $2K |
| 82803 | <1% | 100 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 27 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,815 | $2K |
| 87081 | <1% | 306 | $2K | |
| 74183 | <1% | 26 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $2K |
| 83605 | <1% | 140 | $1K | |
| 82330 | <1% | 95 | $1K | |
| 74019 | <1% | 45 | $908.88 | |
| 84702 | <1% | 58 | $723.50 | |
| 85610 | <1% | 189 | $675.77 | |
| 82565 | <1% | 139 | $630.41 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $594.03 |
| 81002 | <1% | 177 | $533.20 | |
| 74018 | <1% | 31 | $508.37 | |
| 86140 | <1% | 110 | $488.66 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 183 | $439.51 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 38 | $385.40 |
| 84295 | <1% | 75 | $350.44 | |
| 82947 | <1% | 96 | $329.97 | |
| 84520 | <1% | 85 | $294.84 | |
| 84132 | <1% | 64 | $274.95 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 432 | $265.74 |
| 82374 | <1% | 40 | $177.94 | |
| 82977 | <1% | 23 | $161.68 | |
| 85014 | <1% | 74 | $158.25 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 55 | $133.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 56 | $114.00 |
| 82435 | <1% | 25 | $102.25 | |
| 87075 | <1% | 13 | $92.62 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 64 | $55.12 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 952 | $44.40 |
| 87205 | <1% | 13 | $41.80 | |
| A6457 | Tubular dressing with or without elastic, any width, per linear yard | <1% | 13 | $38.28 |
| A4215 | Needle, sterile, any size, each | <1% | 43 | $27.51 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 14 | $18.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 838 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 32 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 581 | $0.00 |
| 99152 | 0% | 292 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 24 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 88 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 12 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 30 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,949 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 955 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 44 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 15 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 26 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 60 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWEED, MICHAEL (VP)
| Provider | Location | Paid |
|---|---|---|
| Integris Ambulatory Care Corporation | Oklahoma City, OK | $27.57M |
| Integris Health Edmond, INC | Edmond, OK | $4.07M |
| Integris Baptist Medical Center INC | Oklahoma City, OK | $2.45M |
| Zuhdi Transplant Physicians | Oklahoma City, OK | $255K |
| Integris Prohealth INC | Oklahoma City, OK | $197K |
| Integris Ambulatory Care Corporation | Enid, OK | $173K |
| Integris Health Allset Urgent Care LLC | Edmond, OK | $104K |
| Integris Prohealth INC | Oklahoma City, OK | $85K |
| Integris Prohealth INC | Enid, OK | $15K |
| Integris Prohealth INC | Oklahoma City, OK | $11K |
| Integris Ambulatory Care Corporation | Bethany, OK | $738.55 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.